GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
S

Scancell Holdings SCLP.L · GBp

Health Care · LSE · 🇬🇧 United Kingdom

Compare

81.00p

-3.57%

Close of 9 Nov 2026, in pence

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Scancell Holdings

Its shares trade on LSE under the ticker SCLP.L. It has been listed since 30 July 2010. In the fiscal year to 30 April 2025, it reported revenue of £4.7m and a net loss of £12.3m. At that date it held total assets of £23.1m and shareholders' equity of −£3.8m.

Scancell Holdings Plc engages in the development of novel therapeutic vaccines for the treatment of cancer. The company is headquartered in Oxford, Oxfordshire. The company went IPO on 2010-07-30. The firm's principal activity consists of the discovery and development of monoclonal antibodies and vaccines for the treatment of cancer. The firm is developing a pipeline of immunotherapies for the treatment of cancer based on its ImmunoBody and Moditope platforms. The firm's products include SCIB1, SCIB2 and Modi-1. The firm's first cancer vaccine, SCIB1, is being developed for the treatment of melanoma and is in Phase I/II clinical trials. SCIB2 contains multiple T cell epitopes derived from the lung cancer associated antigen NY-ESO-1. The company is developed to the point at which the product is defined and ready for further preclinical development as an immunotherapy for any tumor that expresses the NY-ESO-1 antigen. The firm's first Moditope development candidate is Modi-1. Modi-1 consists of two citrullinated vimentin peptides and one citrullinated enolase peptide.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Biotechnology
Listed since
30 Jul 2010
Employees
14

Leadership

Pay as last reported

  • Mr. Jean-Michel CosseryNon-Executive Chairman of the Board£100,000
  • Dr. Phil L'HuillierChief Executive Officer, Executive Director, since 2024£199,445
  • Mr. Sathijeevan NirmalananthanChief Financial Officer, Executive Director, Company Secretary, since 2023£267,750
  • Prof. Lindy DurrantChief Scientific Officer, Executive Director, since 2024£386,797
  • Dr. Nermeen VarawallaChief Medical Officer
  • Mr. Martin DiggleNon-Executive Director
  • Dr. Florian ReinaudNon-Executive Director
  • Ms. Susan DaviesNon-Executive Independent Director£55,000
  • Dr. Ursula NeyNon-Executive Independent Director£40,000

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.